@article{582558faf21748b9a08ee3292a7092ba,
title = "Lifestyle Modifications for Preventing and Treating Heart Failure",
abstract = "Continued improvement in medical and device therapy for heart failure (HF) has led to better survival with this disease. Longer survival and increasing numbers of unhealthy lifestyle factors and behaviors leading to occurrence of HF at younger ages are both contributors to an increase in the overall prevalence of HF. Clinicians treating this complex disease tend to focus on pharmacological and device therapies, but often fail to capitalize on the significant opportunities to prevent or treat HF through lifestyle modification. Herein, the authors review the evidence behind weight management, exercise, nutrition, dietary composition, supplements, and mindfulness and their potential to influence the epidemiology, pathophysiology, etiology, and management of stage A HF.",
keywords = "coenzyme Q10, congestive heart failure, diet, diuretics, exercise, lifestyle, meditation, nitrates, nutrition, obesity, risk modification, sodium, supplements, weight management, yoga",
author = "{American College of Cardiology's Nutrition and Lifestyle Committee of the Prevention of Cardiovascular Disease Council} and Monica Aggarwal and Biykem Bozkurt and Gurusher Panjrath and Brooke Aggarwal and Ostfeld, {Robert J.} and Barnard, {Neal D.} and Hanna Gaggin and Freeman, {Andrew M.} and Kathleen Allen and Shivank Madan and Daniele Massera and Litwin, {Sheldon E.}",
note = "Funding Information: Dr. B. Aggarwal has received research funding from an American Heart Association Go Red for Women Strategically Focused Research Network Award (grant 16SFRN27960011). Dr. Ostfeld has served as a consultant for Better Therapeutics. Dr. Barnard has served, without financial compensation, as president of the Physicians Committee for Responsible Medicine and Barnard Medical Center, a nonprofit organization providing education, research, and medical care related to nutrition. Dr. Gaggin is supported in part by the Clark Fund for Cardiac Research Innovation; has received research grant support from Roche Diagnostics and Portola; has served as a consultant for Amgen, Boston Heart Diagnostics, and Ortho Clinical; and has served on the clinical endpoint committee for EchoSense and Radiometer. Dr. Freeman has done nonpromotional speaking for Boehringer Ingelheim. Dr. Litwin has served on the event adjudication committee for CVRx (Beat HF Trial). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Publisher Copyright: {\textcopyright} 2018 American College of Cardiology Foundation",
year = "2018",
month = nov,
day = "6",
doi = "10.1016/j.jacc.2018.08.2160",
language = "English (US)",
volume = "72",
pages = "2391--2405",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "19",
}
